La création du laboratoire international a pour but la poursuite et le développement de la collaboration dans les domaines scientifique, de formation par la recherche et de transfert technologique dans les deux sens que nous avons établi depuis 2003 sur les facteurs pronostiques et l’efficacité de la réponse thérapeutique dans les lymphomes humains. Grace à deux PRA successifs, nous avons harmonisé le recueil, la gestion et l’analyse des prélèvements tissulaires, et, à l’occasion de trois thèses en cotutelle, transféré la microdissection laser et les microméthodes moléculaires, ainsi qu’un logiciel pour les bases de données. Nous pouvons maintenant étudier en commun les relations entre marqueurs cellulaires et moléculaires d’apoptose et facteurs cliniques. La comparaison de deux grandes séries de lymphomes dans des populations différentes, avec des facteurs génétiques, épigénétiques et dans un environnement différent, nous permettra d’apprécier une éventuelle hétérogénéité dans la fréquence des différents types de lymphomes, et dans les aspects microscopiques et/ou moléculaires. S’il existe des différences, nous en approfondirons l’étude. Si ces facteurs sont similaires sur les deux sites, nous pourrons faire une étude conjointe de grande envergure et envisager des essais thérapeutiques prospectifs.

Ces travaux ont permis la publication de 28 publications communes :

1.         Zhao P, Ji MM, Fang Y, Li X, Yi HM, Yan ZX, et al. A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes. Cell Death Dis. 2021;12(4):321.
2.         Sun R, Zheng Z, Wang L, Cheng S, Shi Q, Qu B, et al. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression. Mol Oncol. 2021;15(1):246-61.
3.         Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, et al. Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther. 2020;5(1):15.
4.         Shen R, Xu PP, Wang N, Yi HM, Dong L, Fu D, et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med. 2020;10(7):e221.
5.         Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679-87.
6.         Fang Y, Wang H, Dou HJ, Fan X, Fei XC, Wang L, et al. Doxorubicin-loaded dextran-based nano-carriers for highly efficient inhibition of lymphoma cell growth and synchronous reduction of cardiac toxicity. Int J Nanomedicine. 2018;13:5673-83.
7.         Zheng Z, Xu PP, Wang L, Zhao HJ, Weng XQ, Zhong HJ, et al. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells. J Exp Clin Cancer Res. 2017;36(1):82.
8.         Xu PP, Sun YF, Fang Y, Song Q, Yan ZX, Chen Y, et al. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Sci Rep. 2017;7(1):7433.
9.         Xiong J, Wang L, Fei XC, Jiang XF, Zheng Z, Zhao Y, et al. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. Blood Cancer J. 2017;7(7):e0.
10.       Shi Q, Shen R, Wang CF, Fan X, Qian Y, Ou-Yang BS, et al. Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients. Mediators Inflamm. 2017;2017:7960907.
11.       Yan ZX, Zheng Z, Xue W, Zhao MZ, Fei XC, Wu LL, et al. MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance. Biomed Res Int. 2015;2015:197241.
12.       Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, et al. Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. Autophagy. 2015;11(12):2160-71.
13.       Zheng Z, Cheng S, Wu W, Wang L, Zhao Y, Shen Y, et al. c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors. J Hematol Oncol. 2014;7:88.
14.       Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y, Romero M, et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia. 2014;28(4):880-7.
15.       Wang L, Romero M, Ratajczak P, Leboeuf C, Belhadj S, Peffault de Latour R, et al. Increased apoptosis is linked to severe acute GVHD in patients with Fanconi anemia. Bone Marrow Transplant. 2013;48(6):849-53.
16.       Ratajczak P, Leboeuf C, Wang L, Briere J, Loisel-Ferreira I, Thieblemont C, et al. BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. Mod Pathol. 2012;25(6):805-14.
17.       Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, et al. Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Haematologica. 2011;96(6):927-31.
18.       Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, et al. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma. Ann Hematol. 2011;90(1):53-8.
19.       Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L, et al. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol. 2010;3:30.
20.       Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia. 2009;23(8):1507-14.
21.       Soltani-Arabshahi R, Leboeuf C, Rivet J, Pisonero H, Zhao WL, Bachelez H, et al. Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. J Invest Dermatol. 2009;129(7):1703-9.
22.       Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood. 2008;111(7):3867-71.
23.       Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, et al. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Exp Hematol. 2007;35(12):1801-11.
24.       Zhao WL, Liu YY, Plassa F, Jin XL, Wang L, Janin A, et al. [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2007;28(10):664-6.
25.       Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):339-44.
26.       Liu YH, Leboeuf C, Jin XL, Xiao JC, Janin A, Chen SJ, et al. [BCL-XL expression and mutation in non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14(5):903-7.
27.       Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004;84(11):1512-9.
28.       Zhao WL, Daneshpouy ME, Mounier N, Briere J, Leboeuf C, Plassa LF, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103(2):695-7.